ACAD ACADIA Pharmaceuticals Inc. - Fundamental Analysis
BULLISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACAD Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$22.03
Analyst Target
$31.21
+41.7%
Upside
52W High
$28.35
52W Low
$13.4
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$3.73B
P/E
13.94
ROE
35.0%
Profit margin
24.9%
Debt/Equity
0.06
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
87%
Analysis Accuracy
ACAD demonstrates strong financial health with a Piotroski F-Score of 7/9, indicating robust operational and profitability fundamentals. The company exhibits exceptional earnings growth (112.8% YoY) and consistent earnings beat history (69.59% average surprise), supported by high margins and low leverage. Despite a bearish insider sentiment due to recent selling activity, the stock trades below its intrinsic value of $46.61 and Graham Number of $13.88, suggesting significant upside potential. Analysts maintain a buy consensus with a target price of $31.21, reflecting confidence in future growth. The absence of an Altman Z-Score is not a concern given the company's strong balance sheet and minimal debt.
Key Strengths
Piotroski F-Score of 7/9 indicates strong financial health and operational efficiency
Exceptional earnings growth (112.8% YoY) and consistent beat rates (3/4 in last 4 quarters)
High gross (59.00%) and profit margins (24.94%), signaling strong pricing power and cost control
Extremely low debt/equity (0.06) and strong liquidity (current ratio 3.02), indicating financial resilience
Intrinsic value ($46.61) significantly exceeds current price ($22.03), suggesting undervaluation
Key Risks
Bearish insider sentiment with $1.3M in sales over 6 months, particularly from CFO and director
Current price is 52% below 52-week high, indicating recent underperformance and potential market skepticism
No PEG ratio available, limiting assessment of growth-to-value alignment
High forward P/E of 28.33 suggests market is pricing in significant future growth, increasing downside risk if expectations are unmet
Lack of dividend and minimal cash flow data may limit appeal to income-focused investors
AI Fair Value Estimate
Based on comprehensive analysis
$46.61
+111.6% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
71
Strong
88
90
87
92
0
AI Verdict
Strong Buy
Key drivers: High Piotroski F-Score (7/9), Exceptional earnings growth and beat history, Strong balance sheet and low leverage, Significant undervaluation relative to intrinsic value, Positive analyst sentiment and target price upside
Confidence
88%
Value
88/100
Ref P/E, PEG, Graham Number
Positives
- Current price ($22.03) is 52.7% below intrinsic value ($46.61)
- Graham Number ($13.88) is well below current price, indicating potential upside
- P/E (13.94) is below sector average (197.66), suggesting relative value
Watchpoints
- Forward P/E (28.33) is elevated, reflecting high growth expectations
- No PEG ratio available, limiting growth-adjusted valuation assessment
Future
90/100
Ref Growth rates
Positives
- 112.8% YoY earnings growth and 119.1% Q/Q earnings growth indicate strong momentum
- Average earnings surprise of 69.59% over last 4 quarters shows consistent outperformance
- Revenue growth of 11.30% YoY supports top-line expansion
- High forward P/E suggests strong market confidence in future growth
Watchpoints
- No Q/Q revenue growth data available, limiting trend visibility
- High growth expectations may be difficult to sustain
Past
87/100
Ref Historical trends
Positives
- 25 consecutive quarters of earnings reporting with consistent beat history
- Recent quarters show dramatic EPS improvement from losses to strong profits
- Positive surprise trends in 2025 (e.g., +292.6% and +189.0%) indicate improving performance
Watchpoints
- Historical losses in 2020–2022 indicate past profitability challenges
- Some quarters showed negative surprises (e.g., -42.3% in 2020)
Health
92/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 7/9 indicates strong financial health and operational stability
- Debt/Equity ratio of 0.06 is extremely low, indicating minimal financial risk
- Current and quick ratios (3.02 and 2.77) show strong liquidity
Watchpoints
- No Altman Z-Score available, but the financial profile suggests low distress risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio (0.00%)
- Dividend strength score of 0/100 indicates no income generation
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$22.03
Analyst Target
$31.21
Upside/Downside
+41.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACAD and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals Inc.
Primary
|
-55.1% | +15.3% | +11.4% | -13.0% | -18.0% | -6.5% |
|
ADMA
ADMA Biologics, Inc.
Peer
|
+507.2% | +348.2% | +0.1% | -5.3% | -12.0% | -2.1% |
|
ACLX
Arcellx, Inc.
Peer
|
+307.7% | +127.2% | +7.5% | -7.5% | -1.9% | +0.7% |
|
BLLN
BillionToOne, Inc.
Peer
|
-19.6% | -19.6% | -19.6% | -19.6% | +1.4% | -1.3% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+176.1% | +531.6% | +52.0% | +66.1% | +4.0% | -0.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
13.94
Forward P/E
28.33
PEG Ratio
N/A
P/B Ratio
4.06
P/S Ratio
3.56
EV/Revenue
2.8
EV/EBITDA
27.06
Market Cap
$3.73B
Profitability
Profit margins and return metrics
Profit Margin
24.94%
Operating Margin
12.83%
Gross Margin
59.0%
ROE
34.95%
ROA
5.11%
Growth
Revenue and earnings growth rates
Revenue Growth
+11.3%
Earnings Growth
+112.8%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+119.1%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.06
Low debt
Current Ratio
3.02
Strong
Quick Ratio
2.77
Excellent
Cash/Share
$5.01
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-25
$N/A
2025-11-05
$0.42
+189.0% surprise
2025-08-06
$0.16
+15.3% surprise
2025-05-07
$0.11
+4.5% surprise
Healthcare Sector Comparison
Comparing ACAD against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
P/E Ratio
13.94
This Stock
vs
197.69
Sector Avg
-92.9%
(Discount)
Return on Equity (ROE)
34.95%
This Stock
vs
-56.84%
Sector Avg
-161.5%
(Below Avg)
Profit Margin
24.94%
This Stock
vs
-20.8%
Sector Avg
-219.9%
(Weaker)
Debt to Equity
0.06
This Stock
vs
2.68
Sector Avg
-97.8%
(Less Debt)
Revenue Growth
11.3%
This Stock
vs
61.93%
Sector Avg
-81.8%
(Slower)
Current Ratio
3.02
This Stock
vs
3.47
Sector Avg
-12.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals Inc.
|
BULLISH | $3.73B | 13.94 | 35.0% | 24.9% | $22.03 | |
|
ADMA
ADMA Biologics, Inc.
|
BEARISH | $3.84B | 18.08 | 63.2% | 42.9% | $16.09 | |
|
ACLX
Arcellx, Inc.
|
BEARISH | $3.96B | - | -47.2% | -% | $68.5 | |
|
BLLN
BillionToOne, Inc.
|
NEUTRAL | $4.01B | - | -% | -4.4% | $87.57 | |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
NEUTRAL | $4.21B | 1339.0 | -% | 0.2% | $13.39 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-09 | RHODES JENNIFER J. | Officer | Sale | 6,950 | $162,491 |
| 2026-02-06 | RHODES JENNIFER J. | Officer | Stock Award | 12,944 | - |
| 2025-11-18 | KIHARA JAMES | Officer | Sale | 4,084 | $96,754 |
| 2025-11-18 | SCHNEYER MARK C. | Chief Financial Officer | Sale | 10,262 | $243,114 |
| 2025-11-17 | KIHARA JAMES | Officer | Stock Award | 7,932 | - |
| 2025-11-17 | SCHNEYER MARK C. | Chief Financial Officer | Stock Award | 19,826 | - |
| 2025-11-10 | DALY JAMES M. | Director | Sale | 30,000 | $670,983 |
| 2025-09-15 | SCHNEYER MARK C. | Chief Financial Officer | Sale | 3,498 | $82,728 |
| 2025-09-12 | SCHNEYER MARK C. | Chief Financial Officer | Stock Award | 6,815 | - |
| 2025-09-02 | GAROFALO ELIZABETH AMY M.D. | Director | Sale | 1,600 | $41,560 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
19 analysts
Oppenheimer
2026-02-06
Perform
Perform
RBC Capital
2026-02-03
Outperform
Outperform
Citizens
2026-02-03
Market Outperform
Market Outperform
HC Wainwright & Co.
2026-02-03
Buy
Buy
Citigroup
2026-01-06
Buy
Buy
UBS
2026-01-06
Buy
Buy
HC Wainwright & Co.
2025-12-15
Buy
Buy
Stifel
2025-12-11
Hold
Hold
Mizuho
2025-12-02
Neutral
Neutral
JP Morgan
2025-11-17
Overweight
Overweight
Past News Coverage
Recent headlines mentioning ACAD from our newsroom.
Newest → oldest
No matching news yet.